
pmc: PMC3217780
The lifetime risk of fracture in white women is 20% for the spine, 15% for the wrist, and 18% for the hip, with an exponential increase in risk beyond the age of 50 years.We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments to prevent fractures in postmenopausal women? We searched: Medline, Embase, The Cochrane Library and other important databases up to January 2007. (BMJ Clinical evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).We found 61 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.In this systematic review we present information relating to the effectiveness and safety of the following interventions: alendronate, calcitonin, calcium, calcium plus vitamin D, clodronate, etidronate, exercise, hip protectors, hormone replacement therapy, ibandronate, multifactorial non-pharmacological interventions, pamidronate, parathyroid hormone, raloxifene, risedronate, strontium ranelate, vitamin D, and vitamin D analogues.
Calcitonin, Selective Estrogen Receptor Modulators, Hormone Replacement Therapy, Administration, Oral, Pamidronate, Fractures, Bone, Patient Education as Topic, Bone Density, Risk Factors, Humans, Vitamin D, Ibandronic Acid, Osteoporosis, Postmenopausal, Aged, Evidence-Based Medicine, Alendronate, Bone Density Conservation Agents, Diphosphonates, Incidence, Managed Care Programs, Etidronic Acid, Middle Aged, Prognosis, United States, Calcium, Dietary, Postmenopause, Fractures, Spontaneous, Parathyroid Hormone, Raloxifene Hydrochloride, Women's Health, Calcium, Female, Clodronic Acid, Family Practice, Risedronic Acid, Osteoporotic Fractures
Calcitonin, Selective Estrogen Receptor Modulators, Hormone Replacement Therapy, Administration, Oral, Pamidronate, Fractures, Bone, Patient Education as Topic, Bone Density, Risk Factors, Humans, Vitamin D, Ibandronic Acid, Osteoporosis, Postmenopausal, Aged, Evidence-Based Medicine, Alendronate, Bone Density Conservation Agents, Diphosphonates, Incidence, Managed Care Programs, Etidronic Acid, Middle Aged, Prognosis, United States, Calcium, Dietary, Postmenopause, Fractures, Spontaneous, Parathyroid Hormone, Raloxifene Hydrochloride, Women's Health, Calcium, Female, Clodronic Acid, Family Practice, Risedronic Acid, Osteoporotic Fractures
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 24 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
